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Systematic reviewers conducting pairwise meta-analyses sometimes encounter multi-
arm studies. To include these studies, in order to avoid a unit-of-analysis error, often
two or more arms are combined or the control arm is split up. In this tutorial we
present five different approaches that can be used. Particularly, we present a novel
approach (Method 4) that to the best of our knowledge has not been presented
before. We demonstrate their application on three selected data sets, discuss their
scope of application and their advantages and limitations, and give recommenda-
tions.
Main text: ca. 4370 words
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1 Introduction
Until ten years ago, almost all systematic reviews exclusively used standard pairwise
meta-analysis. It is probably still the most frequent mode of meta-analysis in the
literature. More recently, reviews have increasingly used network meta-analysis.
The first Cochrane review including a network meta-analysis was published in 2010
(Walsh et al., 2010). Researchers conducting a systematic review have the choice
between pairwise meta-analysis and network meta-analysis. Which method to use
depends on the research question. Pairwise meta-analysis is the method of choice
for researchers interested in a particular comparison, for example comparing a new
treatment with a generally accepted standard of care, or asking whether a treatment
is efficacious at all (compared to no treatment or placebo).
When searching the literature, reviewers planning a pairwise meta-analysis some-
times encounter multi-arm studies, where, say, two or more dosages of an interesting
drug treatment are compared to a common control, for example placebo. If the re-
search question is to compare the drug in all dosages to placebo, all comparisons
(also called relative effects or contrasts) to placebo could and should be included
in the same meta-analysis. However, as there is only one control group, one has to
make sure that each patient enters the meta-analysis only once, in order to avoid a
unit-of-analysis error. A unit-of-analysis error in a meta-analysis is said to occur if
information from a treatment arm is used more than once or with disproportionate
weight. For example, combining comparisons of three different dosages of an active
treatment to the same full placebo group without any adjustment would mean using
the patients of the placebo group thrice. This is a problem because comparisons us-
ing the same individuals are correlated. It is clearly a methodogical flaw. To avoid
this, often the control group is randomly partitioned into two or more subgroups,
each of which is compared to another active group. The shared group could also
be the active group instead of the control group which is illustrated using a ficti-
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tious example in section 16.5.4 (How to include multiple groups from one study)
of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins and
Green, 2011, Version 5.1.0). The Cochrane Handbook provides general guidelines
for meta-analysis with multiple treatment groups and lists a number of possible ways
to include these data.
The first approach (which is recommended by Cochrane) is to combine all groups
that represent different modalities of a treatment to a single large group. For the
example, this results in combining two or more dosage groups. Technically, in the
case of a binary outcome this is easily done by summing up the numbers of events
and the total numbers of individuals across all groups involved. Section 7.7.3.8 of
the Cochrane Handbook (Table 7.7.a) provides formulas for calculating mean and
standard deviation of a combined group in case of a continuous outcome, given
summary data for the two groups that are to be combined. This can also be done
using the calculator in RevMan 5.3 (The Cochrane Collaboration, 2014).
The second approach is to split the shared group into subgroups of (nearly) equal
size, one for each treatment. For the example, this is applied to the placebo group.
Again, in the case of a binary outcome, this is straightforward, except that the
total number of events or sample size may not be possible to split into equal parts
according to the number of active treatment arms (in the extreme, we can have a
study with less events in the control group than the number of active study arms).
For a continuous outcome, only the total number of participants is divided up,
assuming equal means and standard deviations in all subgroups. This approach is
not generally recommended, as only the unit-of-analysis error is avoided, while the
groups are still correlated because the means are equal.
Another approach mentioned in the Cochrane Handbook is to include two or more
correlated comparisons in the meta-analysis and account for the correlation. The
final proposal is to conduct a multiple treatment meta-analysis, also called network
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meta-analysis, which generalizes pairwise meta-analysis to more than two treat-
ments. In this respect, it goes beyond the scope of a systematic review that aims at
comparing two interventions, based on pairwise meta-analysis. Following this recom-
mendation of the Handbook means shifting the research question from a pairwise
comparison to a multiple treatment comparison. The approach is therefore more
than just another adjusting method. Because in network meta-analysis all com-
parisons provide information, the analysis benefits from full information, but must
account for the correlation between three or more comparisons within the same trial.
Appropriate methods of network meta-analysis adjust for the correlation between
multiple comparisons within multi-arm studies (Franchini et al., 2012; Ru¨cker and
Schwarzer, 2014).
The objective of this tutorial is to present five approaches (three of which have been
mentioned above), to demonstrate their application on three selected data sets, and
to discuss their scope of application as well as their advantages and limitations.
Particularly, we add a novel approach (Method 4 below) that to the best of our
knowledge has not been presented before.
The paper is organised as follows. In section 2, the data examples are presented,
the first with a binary outcome, the second with a continuous outcome and the
third with a survival outcome. In section 3, subsection 3.1, three different potential
purposes of a meta-analysis are listed. In subsection 3.2, the five methods are
described and illustrated by applying them to the first example. In subsection 3.3
we discuss how to proceed if some information is missing. In section 4 all methods
are applied to the other two examples. The paper concludes with a discussion and
some recommendations in section 5.
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2 Data sets
2.1 Pelargonium sidoides data
Our first data example comes from a Cochrane review comparing pelargonium
sidoides, also known as Umckaloabo, for treatment of acute respiratory infections to
placebo (Timmer et al., 2013). One of the trials included was a four-arm trial with
three different treatment arms and a placebo arm (Kamin et al., 2010). The out-
come is ‘Failure to recover by day seven’ (i.e., complete resolution of all symptoms),
dichotomous data are shown in Table 1. In the Cochrane review the ‘Splitting the
shared group’ approach was used and the trial was reported as three substudies (10
mg, 20 mg, 30 mg), each compared with a third of the number of controls. This
data set serves for illustration of all methods in this section of the tutorial.
Table 1: Pelargonium sidoides data by Kamin 2010.
study treatment event n
Kamin 2010 pelargonium sidoides 10 mg 91 100
Kamin 2010 pelargonium sidoides 20 mg 82 99
Kamin 2010 pelargonium sidoides 30 mg 87 99
Kamin 2010 placebo 92 101
2.2 Acupuncture data
In a three-arm trial (Linde et al., 2005), acupuncture for migraine was compared to
sham acupuncture and to a waiting list. To facilitate recruitment and increase the
compliance of trial physicians, a 2:1:1 randomisation ratio was used. The primary
outcome was the reduction in the number of days with headache of moderate or
severe intensity between the 4 weeks before and weeks 9 to 12 after randomization,
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based on patients’ diaries. Results are given in Table 2.
Table 2: Acupuncture data by Linde 2005
study treatment n mean (days) SD
Linde 2005 acupuncture 145 2.2 2.7
Linde 2005 sham acupuncture 81 2.2 2.7
Linde 2005 waiting list 76 0.8 2.0
2.3 Breast cancer data
The last example comes from a three-arm phase III trial investigating the efficacy
and safety of three combination treatments for human epidermal growth factor recep-
tor 2 (HER2)-negative, locally recurrent or metastatic breast cancer (Miles et al.,
2010). The three arms were docetaxel 100 mg/m2 plus bevacizumab 15 mg/kg
(n = 247), docetaxel 100 mg/m2 plus bevacizumab 7.5 mg/kg (n = 248), and do-
cetaxel 100 mg/m2 plus placebo (n = 241). The results for the primary endpoint
progression-free survival (PFS) are given in Table 3.
Table 3: Breast cancer data by Miles 2010
study treatment 1 treatment 2 HR [95% CI]1
docetaxel 100 plus docetaxel 100 plus
Miles 2010
bevacizumab 15 placebo
0.77 [0.64; 0.93]
docetaxel 100 plus docetaxel 100 plus
Miles 2010
bevacizumab 7.5 placebo
0.86 [0.72; 1.04]
1HR = hazard ratio; CI = confidence interval
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3 Methods
3.1 The purpose of the meta-analysis
When deciding how to handle multiple groups in a pairwise meta-analysis it is
important to consider which is the purpose of the meta-analysis (note that the
intention of the meta-analysis, as part of a systematic review, may differ from that
of a primary study). The following questions are selected from an abundance of
possible research questions:
1. Is treatment A efficacious, compared to placebo?
2. Is treatment A, in any application, efficacious compared to placebo?
3. Is treatment A efficacious, compared to placebo or no treatment?
4. Is A combined with B better than A alone?
5. Which of treatments A, B, C, . . . is best with respect to efficacy?
Questions 1, 2 and 4 lead to pairwise meta-analysis, question 3 may suggest pairwise
meta-analysis (if we are not interested in comparing placebo with no treatment), or
network meta-analysis (if we are interested in comparing placebo with no treatment),
only question 5 undoubtedly requires network meta-analysis.
The various types of questions may occur in different clinical areas with different
probabilities. In areas with an abundance of treatments (for example, depression),
network meta-analysis is the method of choice. In other fields, a research question
may be much more focussed, suggesting pairwise meta-analysis, for example, when
comparing a certain surgical technique with another technique, or deciding whether
surgery is necessary at all (illustrated by the title of a review ‘To close or not to
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close: contemporary indications for patent foramen ovale closure’ Zier et al. (2016)).
To give these scenarios a structure, we distinguish three common cases.
1. Two treatments are compared. The distinction between different modalities
of the active treatment or subtypes of the control treatment is not important
for the research question at hand.
2. Two treatments are compared, but it is also of interest whether the treatment
modality or the type of control treatment makes a difference.
3. The meta-analysis is designed as a network meta-analysis to determine a rank
order of benefit, and the literature search was designed to find studies com-
paring at least two of the eligible treatments.
In the first case one would likely prefer to combine the treatment groups or con-
trol groups. This leads to our Method 1, ‘Combining groups’. In the second case,
there are a number of different options. First, one could split up the shared group
(in example 2.1, this is the placebo group) into a number of subgroups (e.g., three
placebo subgroups, corresponding to the three doses of the active treatment) and
include these as substudies in the meta-analysis. We call this Method 2 (‘Split-
ting the shared group’). In the meta-analysis context, this enables meta-regression,
using the factor defining the subgroups (e.g., dosage) as a covariate. Alternatively,
instead of formally splitting up the shared group, one could compare each treatment
subgroup to the full group, but account for multiplicity by appropriately adjusting
the standard error. There are two ways for doing this, which we call Method 3
(‘Approximate adjustment’) and Method 4 (‘Exact adjustment’). In the third com-
mon case, it is possible to conduct a network meta-analysis, which we call Method
5 (‘Network meta-analysis’). In the next subsection we describe all five methods in
more detail and illustrate each of them practically by application to the first data
set, 2.1.
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3.2 Methods for including multiple groups into a meta-analysis
Method 1: ‘Combining groups’
For a binary outcome, as in the first example data set, combining, i.e., merging the
groups simply means adding the numbers of events and total participants over all
groups. This provides the data in Table 4 and leads to a risk ratio (RR) of 0.96
with a 95% confidence interval (CI) of [0.89; 1.03] (inverse variance method).
Table 4: ‘Combining groups’ applied to the pelargonium sidoides data.
active treatment control
pelargonium sidoides placebo
(10/20/30 mg)
study events n events n
Kamin 2010 260 298 92 101
Section 7.7.3.8 of the Cochrane Handbook (Table 7.7.a) provides formulas for cal-
culating mean and standard deviation in case of a continuous outcome, if summary
data over all groups or individual patient data are not available. Given the sample
sizes n1, n2, the means x¯1, x¯2 and the standard deviations SD1, SD2, we obtain for
the combined group
ncomb = n1 + n2 (1)
x¯comb =
n1x¯1 + n2x¯2
n1 + n2
(2)
SDcomb =
√
(n1 − 1)SD21 + (n2 − 1)SD22 + n1n2n1+n2 (x¯1 − x¯2)2
n1 + n2 − 1 . (3)
If we have arm-based survival data for two (or more) arms in form of Kaplan-Meier
curve estimates or numbers of events and numbers at risk for all time points, these
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arms can be combined in a straightforward way. For detailed methods of extraction
for survival data, see Parmar et al. (1998); Tierney et al. (2007).
Method 2: ‘Splitting the shared group’
This method was applied in the Cochrane review that included the study of the first
example. The control group was randomly split in three groups, leading to the data
in Table 5. Meta-analysis using the common effect model with the Mantel-Haenszel
method resulted in a pooled RR of 0.96 with a 95% CI of [0.89; 1.03], which is
in agreement with the result of method 1. Using the inverse variance method in
analogy to Method 1 leads to a pooled RR of 0.96 [0.89; 1.04]. Due to the different
weighting, there is a slight difference seen in the confidence interval.
Table 5: ‘Splitting the shared group’ applied to the pelargonium sidoides data.
active treatment control
pelargonium sidoides placebo
study events n events n
Kamin 2010, 10 mg 91 100 31 34
Kamin 2010, 20 mg 82 99 30 33
Kamin 2010, 30 mg 87 99 31 34
Method 3: ‘Approximate adjustment’
This method has been proposed by one of the authors of this tutorial (Cates, 2015),
and can be used to avoid unit of analysis errors when including multi-arm trials in
a generic inverse variance meta-analysis. It is based on the following consideration.
Instead of formally splitting up the shared group into groups of (nearly) equal size
and (nearly) equal numbers of events, we could compare each active group to the full
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control group, but increase the standard error of this comparison by an appropriate
factor. This can be derived as follows.
Let k be the total number of arms in the study including the control arm. In our
example, we have k = 4. Comparing each active arm to the kth group (the control
group), we observe variance estimates vik for all k − 1 pairwise comparisons of arm
i to arm k. These can be assumed to be sums of the respective arm-based sampling
variances s2i and s
2
k, that is
vik = s
2
i + s
2
k (i = 1, . . . , k − 1).
Splitting the control group into k − 1 equal parts means increasing the variance in
the control group, s2k, by the factor k−1. Accounting for multiple use of the control
group therefore means that we have to consider the adjusted variances
vadjik = s
2
i + (k − 1)s2k (i = 1, . . . , k − 1)
instead of vik. The variance of the na¨ıvely pooled common effect estimate is
Var unadj =
1∑k−1
i=1
1
vik
=
1∑k−1
i=1
1
s2i+s
2
k
and the variance of the pooled common effect estimate based on the adjusted vari-
ances is
Var adj =
1∑k−1
i=1
1
v
adj
ik
=
1∑k−1
i=1
1
s2i+(k−1)s
2
k
.
We obtain for the variance inflation factor
Var adj
Var unadj
=
∑k−1
i=1
1
s2i+s
2
k∑k−1
i=1
1
s2i+(k−1)s
2
k
.
If all arms including the control arm are of approximately equal size, we may estimate
the variance inflation factor by assuming that all within-group standard errors are
equal, that is, s2i = s
2(i = 1, . . . , k). Then the approximate variance inflation factor
becomes
Var adj
Var unadj
=
k
2
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and the inflation factor for the standard error is
√
k/2. Applying this to the example
(k = 4) means first comparing all active arms to the (unsplit) control arm by
calculating pairwise RRs and then inflating the standard error of each RR by
√
2
before performing meta-analysis. For the example, this results in a pooled RR of
0.96 with a 95% CI of [0.89; 1.04], which is in accordance to those of methods 1 and
2 (Figure 1).
We note that Method 3 can be applied to a more general situation. Let us consider
a k-arm study, where kT arms are interpreted as active arms and kC arms as control
arms (k = kT + kC). The aim is to compare ‘active’ to ‘control’ in a pairwise meta-
analysis, given all kT × kC pairwise comparisons of active treatments with control
treatments, like in Figure 2 with kT = 2, kC = 3. Of course, simply pooling all
comparisons in a meta-analysis would lead to a unit-of-analysis error. Assuming
equal standard errors in all arms, we have for each of the kT × kC contrasts a
sampling variance of s2 + s2 = 2s2 (without adjustment).
Splitting each arm using Method 2 (’Splitting the shared group’) would lead to di-
viding each of the active arms into kC equal parts (one for each control arm) and
each of the control arms into kT equal parts (one for each active arm). Adjusting
the variances thus leads to multiplying the variance of each active arm by kC and
multiplying the variance of each control arm by kT . Accordingly, each comparison
obtains the variance kCs
2+kT s
2 = ks2. Compared to naive pooling without adjust-
ment, we again have a variance inflation factor of ks2/(2s2) = k/2 for the variance
und
√
k/2 for the standard error.
Method 4: ‘Exact adjustment’
Method 3 is an approximate method, because it is based on the simplifying assump-
tion that the standard errors in all arms were equal. However, this might not be the
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case if the arms are of different size. It is particularly questionable in the case of
binary data if the number of events varies across arms, as the variance also depends
on the number of events. To overcome this, we propose to adjust the standard
errors by exact inflation factors that can be derived using a method that was devel-
oped for adjusting the standard errors of multi-arm studies in network meta-analysis
(Ru¨cker and Schwarzer, 2014). The method basically reverses what happens with
the variances in a multi-arm study. Whereas precision in multi-arm studies benefits
from multiple comparisons, we have to reverse this when using only a part of the
comparisons.
For a k-arm study we have k(k−1)/2 comparisons. We consider the variances of all
pairwise comparisons of arms i and j with arm-based sampling variances s2i and s
2
j ,
vij = s
2
i + s
2
j .
For the k-arm study we now define the full design matrix X with dimension k(k −
1)/2×k. As all effects are determined by the k−1 contrasts to an arbitrary reference
treatment, X has rank k − 1. For example, for k = 4 we have k(k − 1)/2 = 6 and
X =


1 −1 0 0
1 0 −1 0
1 0 0 −1
0 1 −1 0
0 1 0 −1
0 0 1 −1


(4)
with rank 3. Let V be a k × k matrix containing the k(k − 1)/2 contrast-based
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sampling variances vij , ordered in the following way (example for k = 4):
V =


0 v12 v13 v14
v12 0 v23 v24
v13 v23 0 v34
v14 v24 v34 0


. (5)
Then the matrix L defined by
L =
(
− 1
2k2
X⊤XVX⊤X
)+
(where the + symbol denotes the pseudoinverse operator (Albert, 1972)) contains as
off-diagonal elements the negative inverses of the inflated variances, ordered in the
same way as in V (Xiao and Gutman, 2004; Ru¨cker, 2012; Ru¨cker and Schwarzer,
2014).
For arbitrary k we provide R code, based on the R package netmeta, in Appendix
A of this article (R Core Team, 2014; Ru¨cker et al., 2017). For k = 3, the inflated
variances vadjij can also be calculated by hand, see Appendix B. Applying exact
adjustment to the first example leads to a pooled RR of 0.97 with a 95% CI of [0.90;
1.04] (Figure 3).
We note that Method 4 not only corrects the standard errors, but also adjusts for
the correlation between multiple comparisons within the same study (Ru¨cker and
Schwarzer, 2014).
Method 5: ‘Network meta-analysis’
Network meta-analysis is an extension of pairwise meta-analysis, used to compare
three or more treatments for a given medical condition, based on combining informa-
tion from all existing comparisons among the treatments from a number of studies
(Salanti, 2012; Ru¨cker, 2016). Typically, also multi-arm studies are included. One
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or more studies comparing different dosages (say) to each other and/or placebo can
be pooled in a network meta-analysis, providing amalgamated direct and indirect
evidence for each possible comparison. For the pelargonium sidoides data, network
meta-analysis would be of particular interest if there were more studies reporting
results stratified by dosage. Figure 4 shows the result for our pelargonium sidoides
study, interpreted as a network meta-analysis of a single study. The standard errors
are not adjusted, as the arms are not merged or split. We do not go into more
detail here, as this is beyond the scope of this article in which our main focus is on
pairwise meta-analysis.
3.3 Missing information
In the pelargonium sidoides example we have full information for all arms. In
practice, however, information may be missing, particularly in case of a continuous
outcome. Often only contrast-based variances are known, and not all of them are
reported in the primary studies. In this subsection, we consider such situations and
show which methods can be chosen.
All contrast-based sampling variances known
If variances are provided for all possible contrasts (comparisons), we know matrix
V as in equation (5) and can use methods 3 (approximate adjustment) and 4 (exact
adjustment). In this case it is possible to derive all arm-based variances, as shown in
Appendix C. If the treatment effects are also available for all contrasts, one can set
one arm effect, considered as a baseline (for example, the placebo effect), formally to
zero (or any other value, because this value cancels out). Then all other arm-based
responses are determined, and we can continue as if having full information and also
use methods 1 (combining groups), 2 (splitting the shared group), and 5 (network
16
meta-analysis).
Only a subset of the contrast-based sampling variances known
If not all contrast-based sampling variances are known, but only those that compare
each treatment to the control, we either may use method 3 (approximate adjustment)
or use method 4 (exact adjustment) after imputing missing information. We show
how the latter works for k = 3. Assume we know the variances v13 and v23. Then
we may estimate v12 by v12 = (v13 + v23)/2 and use exact adjustment.
Alternatively, and particularly if the arms are of different sizes n1, n2, n3, we could
suppose a common standard deviation SD for all arms and assume
v12 =
SD2
n1
+
SD2
n2
(6)
v13 =
SD2
n1
+
SD2
n3
(7)
v23 =
SD2
n2
+
SD2
n3
(8)
Equations 7 and 8 provide
SD2 = v13
n1n3
n1 + n3
SD2 = v23
n2n3
n2 + n3
and we may estimate SD2 as a mean from these:
SD2 =
1
2
(
v13
n1n3
n1 + n3
+ v23
n2n3
n2 + n3
)
Inserting this in (6) we obtain
v12 =
n3
2
(
n1 + n2
n1n2
)(
n1v13
n1 + n3
+
n2v23
n2 + n3
)
. (9)
Table 6 summarises when each method can be applied.
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Table 6: Required data for application of the adjustment methods.
Available data
Method Arm-based Contrast-based Contrast-based data
response data data for only for the contrast
for all arms all contrasts to the shared group
Combining groups yes yes1 no
Splitting the shared group yes yes1 no
Approximate adjustment yes yes yes
Exact adjustment yes yes yes, imputation necessary
Network meta-analysis yes yes yes, imputation necessary
1Setting one arm effect, considered as a baseline, formally to zero
4 Application to the other data sets
In this section we apply the different methods to the other two example data sets.
4.1 Acupuncture data
Suppose that a meta-analysis of ‘all types of acupuncture versus no treatment’
would consider studies of either ‘acupuncture versus waiting list’ or studies of ‘sham
acupuncture versus waiting list’ to be eligible for inclusion.
Method 1: ‘Combining groups’
As the outcome ‘reduction in days with moderate or severe headache’ is a continu-
ous outcome, we have to use the formulas given in section 7.7.3.8 of the Cochrane
Handbook (Table 7.7.a) for combining the acupuncture and the sham acupuncture
group. Given the sample sizes n1, n2, the means x¯1, x¯2 and the standard deviations
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SD1, SD2 from Table 2 and using equations (1) to (3), we obtain for the combined
group ncomb = 226, x¯comb = 2.2, SDcomb = 2.69. Comparing this to the waiting list
group provides a mean difference of 1.4 with a 95% CI of [0.83; 1.97].
Method 2: ‘Splitting the shared group’
Splitting the waiting list group leads to two formal waiting list groups each having
38 patients with means 0.8 and standard deviations 2. Comparing the acupuncture
group to one of them and the sham acupuncture group to the other and pooling this
in a meta-analysis results in a mean difference of 1.4 with a 95% CI of [0.82; 1.98]
(Figure 5).
Method 3: ‘Approximate adjustment’
Approximate adjustment means multiplying the standard errors for each of the
comparisons, acupuncture vs waiting list and sham acupuncture vs waiting list,
with the factor
√
3/2 and pooling the results in a meta-analysis. This results in a
mean difference of 1.4 with a 95% CI of [0.81; 1.99] (Figure 6).
Method 4: ‘Exact adjustment’
Choosing method 4 ‘Exact adjustment’, we can use the R package netmeta to cal-
culate the exact inflated standard errors (R code see Appendix A), or, alternatively,
we can calculate the inflated standard errors using the formulas in Appendix B.
Using the latter method we obtain
S = 0.5(2 ·0.372 ·0.322+2 ·0.372 ·0.382+2 ·0.322 ·0.382−0.374−0.324−0.384) = 0.02
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and the variances
vadj12 =
S
−0.372 + 0.322 + 0.382 = 0.23
vadj13 =
S
0.372 − 0.322 + 0.382 = 0.13
vadj23 =
S
0.372 + 0.322 − 0.382 = 0.24.
This leads to adjusted standard errors
√
vadj13 = 0.36 and
√
vadj13 = 0.49 for the
comparisons ‘acupuncture versus waiting list’ and ‘sham acupuncture versus waiting
list’. Combining both groups with the adjusted standard errors in a meta-analysis
results in a mean difference of 1.4 with a 95% CI of [0.83; 1.97] (Figure 7). We
note that the exact variance inflation factors for the three comparisons (1.61, 1.29,
1.66) differ from their approximate value of 3/2 due to the unbalanced group sizes.
For this reason the exact adjustment method best reproduces the result from the
‘Combining groups’ approach.
Method 5: ‘Network meta-analysis’
Figure 8 shows the results of network meta-analysis applied to the acupuncture
data, with ‘waiting list’ as reference. As for the pelargonium sidoides data, this
analysis simply reproduces the result of the three-arm study without adjustment,
as no merging or splitting of groups is necessary or intended.
4.2 Breast cancer data
The breast cancer data are an example of missing information. We have only
contrast-based information (hazard ratios) for two of the three comparisons, do-
cetaxel 100 + bevacizumab 15 and 7.5, respectively, vs docetaxel 100 + placebo.
Thus, to compare bevacizumab in either dosage to docetaxel alone, the arm-based
methods 1 and 2 are not possible. We may use the contrast-based methods 3 (ap-
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proximate adjustment) or 4 (exact adjustment, that requires imputation of further
information, using methods from subsection 3.3).
Method 3: ‘Approximate adjustment’
For the given contrasts, we can use the estimated hazard ratios and the confidence
intervals to derive the log hazard ratios ln 0.77 = −0.2614 and ln 0.86 = −0.1508
with standard errors 0.0953 and 0.0938. Multiplying the standard errors with
√
3/2
provides adjusted standard errors 0.1168 and 0.1149. Using these in a meta-analysis
to pool the bevacizumab arms results in a pooled HR of 0.81 with 95% CI of [0.69;
0.96] (Figure 9).
Method 4: ‘Exact adjustment’
The variance of the missing comparison (bevacizumab 15 vs bevacizumab 7.5) can be
estimated using equation (9). We obtain 0.0939 for the missing contrast-based stan-
dard error. We may now use the R code in appendix A or the formulas in appendix
B for exact adjustment of the standard errors, giving 0.1180 for bevacizumab 15 vs
docetaxel alone and 0.1142 for bevacizumab 7.5 vs docetaxel alone. Using these in
a meta-analysis to pool the bevacizumab arms results in a pooled HR of 0.82 with
95% CI of [0.69; 0.96] (Figure 10).
Method 5: ‘Network meta-analysis’
Figure 11 shows the results of network meta-analysis applied to the breast can-
cer data, with docetaxel 100 + placebo as reference. Again, this analysis almost
reproduces the result of the three-arm study.
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5 Discussion
Pairwise meta-analysis still dominates the literature of systematic reviews. Even
in reviews using network meta-analysis as primary analysis, pairwise meta-analyses
are routinely conducted and also additionally requested by recent guidelines (Puhan
et al., 2014; Caldwell et al., 2016). In addition to network meta-analysis, which is
designed for comparing more than two treatments in a systematic review, we have
presented four methods for including multiple arms from a multi-arm study in a
pairwise meta-analysis. Some type of adjustment is necessary when doing this to
avoid a unit-of-analysis error.
We distinguished different purposes for including multiple arms. If some arms are to
be combined, as their distinction is not relevant for the research question at hand,
the ‘Combining groups’ method can be chosen. If one decides to analyse the arms
separately, one should choose one of the other methods (splitting the shared group,
approximate adjustment, exact adjustment, or network meta-analysis). Whereas
approximate adjustment is always possible, group-splitting, exact adjustment and
network meta-analysis make some requirements with respect to data availability.
We showed how missing information can be imputed, if necessary.
If the common effect model (traditionally called fixed effect model) is used for pool-
ing, the relative weight of a multi-arm study does not depend on whether its arms
are combined (Method 1) or split up (Methods 2, 3, and 4). When using the ran-
dom effects model, however, the relative weight of each study may depend on the
method for adjusting. Suppose, for example, that there is heterogeneity between
the comparisons of different active arms of a multi-arm study to a common control.
This heterogeneity is hidden if these arms are combined (Method 1), but it becomes
apparent if the control group is split up (Methods 2, 3, and 4). Accordingly, the
estimate for the between-study variance τ 2 may change when using one of these
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methods, which in turn affects all random effect weights, also those of other studies.
Furthermore, if a control arm is split up into two or more parts, τ 2 enters more than
one line in the data, and the study will effectively obtain more weight in the meta-
analysis (particularly if τ 2 is large compared to the study variance) in comparison to
combining the active arms. For this reason, we explicitly discourage using Methods
2, 3, and 4 when using the random effects model.
Conclusion
If a pairwise meta-analysis is planned based on the common effect model, we recom-
mend using the ‘Combining groups’ or the ‘Exact adjustment’ approach, whenever
possible. The ‘Splitting the shared group’ approach seems somewhat arbitrary. In
our examples the ‘Approximate adjustment’ method also provided similar results
to the ‘Combining groups’ and the ‘Exact adjustment’ approaches. Methods ‘Split-
ting the shared group’, ‘Approximate adjustment’ and ‘Exact adjustment’ should
be avoided when using the random effects model. When planning a systematic re-
view where several treatments are available, or treatments are available in different
dosages, pharmaceutical forms or settings, network meta-analysis should always be
considered as an alternative to pairwise meta-analysis.
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A R code for approximate and exact adjustment
In practice, if all variances are given or imputed, determining inflation factors for
arbitrary k is possible using the R package netmeta for network meta-analysis. We
show R code for the pelargonium sidoides example.
# Install package netmeta and make it available in R session
install.packages("netmeta")
library(netmeta)
# Data set by Kamin et al. (2010)
kamin <- data.frame(study = rep("Kamin 2010", 4),
treatment = c("10 mg", "20 mg", "30 mg", "placebo"),
n.failures = c(91, 82, 87, 92),
n.patients = c(100, 99, 99, 101))
# Use pairwise() to obtain pairwise contrasts
# with risk ratio (RR) as effect measure
p.kamin <- pairwise(event = n.failures, n = n.patients,
treat = treatment, studlab = study,
data = kamin,
sm = "RR")
p.kamin
# Conduct network meta-analysis
# (to calculate adjusted standard errors)
net <- netmeta(TE, seTE, treat1, treat2, studlab,
data = p.kamin)
# Print adjusted standard errors:
as.data.frame(net)[, 1:6]
# Forest plot (Figure 4)
forest(net, ref = "placebo", leftlab = "Comparison to placebo")
# Calculate approximately adjusted standard errors
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# with inflation factor sqrt(n / 2) = sqrt(2)
infl <- sqrt(net$n / 2)
seTE.approx <- infl * net$seTE
# Print unadjusted and adjusted standard errors
data.frame(comparison = rownames(net$Cov.fixed),
unadjusted = net$seTE,
approximate = seTE.approx,
exact = net$seTE.adj)
B Determining inflated variances for k = 3
In this subsection, we show how to obtain exactly adjusted standard errors by hand for
k = 3. We have
L =
1
S


2v23 v12 − v13 − v23 −v12 + v13 − v23
v12 − v13 − v23 2v13 −v12 − v13 + v23
−v12 + v13 − v23 −v12 − v13 + v23 2v12


with
S =
1
2
(
2v12v13 + 2v12v23 + 2v13v23 − v212 − v213 − v223
)
.
The inflated variances v∗ij are obtained from the negative inverses of the off-diagonal:
v∗12 =
S
−v12 + v13 + v23
v∗13 =
S
v12 − v13 + v23
v∗23 =
S
v12 + v13 − v23
The adjusted standard errors are obtained by taking the square roots of v∗12, v
∗
13, v
∗
23. The
weight reduction factors f12, f13, f23 are given by
f12 =
v12
v∗12
=
v12(−v12 + v13 + v23)
S
f13 =
v13
v∗13
=
v13(v12 − v13 + v23)
S
f23 =
v23
v∗23
=
v23(v12 + v13 − v23)
S
.
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The average weight reduction factor is
1
3
(f12 + f13 + f23) =
−v212 − v213 − v223 + 2v12v13 + 2v12v23 + 2v13v23
3S
=
2S
3S
=
2
3
,
not depending on the variances. This again leads to the approximate adjusting method
and is a special case of the general case of k arms, where the average weight reduction
factor is 2/k (Ru¨cker 2012). The inverse of the average weight reduction factor, here 3/2
(in general k/2) is thus the harmonic mean of the variance inflation factors.
C Determining arm-based variances from contrast-
based variances
If variances are provided for all possible contrasts, we can derive arm-based variances from
these. This works as follows. For a k-arm study, the design matrix X is that of a complete
graph of k vertices and k(k − 1)/2 edges as in equation (4). Taking the first k rows of its
absolute version |X|, we obtain a quadratic matrix, such as
A =


1 1 0 0
1 0 1 0
1 0 0 1
0 1 1 0


with rank k (here k = 4). Taking the first k of the contrast-based variances, arranged in
the same order as in matrix V (equation(5)), i.e., v = (v12, v13, v14, v23), we can derive the
underlying arm-based variances s = (s21, . . . , s
2
k)
⊤ by solving the equation As = v which
yields
s = A−1v.
26
References
Albert, A. E., 1972. Regression and the Moore-Penrose Pseudoinverse. Mathematics in
Science and Engineering. Academic Press, New York, ISBN: 0-12-048450-1.
Caldwell, D. M., Ades, A. E., Dias, S., Watkins, S., Li, T., Taske, N., Naidoo, B.,
Welton, N. J., Jul 16 2016. A threshold analysis assessed the credibility of conclu-
sions from network meta-analysis. Journal of Clinical Epidemiology 80, 68–76, doi:
10.1016/j.jclinepi.2016.07.003.
Cates, C., 2015. Multiple-arm trial data: using a corrected standard error for GIV
analyses. Cochrane Database of Systematic Reviews Suppl 1-327.
URL http://www.cochranelibrary.com/dotAsset/5bc8d6fd-0604-4bed-beb2-8bc7a74aa4b9.
pdf
Franchini, A. J., Dias, S., Ades, A. E., Jansen, J. P., Welton, N. J., July 20 2012. Account-
ing for correlation in network meta-analysis with multi-arm trials. Research Synthesis
Methods 3 (2), 142–160, dOI: 10.1002/jrsm.1049.
Higgins, J. P., Green, S., 2011. Cochrane Handbook for Systematic Reviews of Interven-
tions Version 5.1.0. The Cochrane Collaboration.
URL http://www.cochrane-handbook.org
Kamin, W., Maydannik, V. G., Malek, F. A., Kieser, M., 2010. Efficacy and tolerability
of EPs 7630 in patients (aged 6-18 years old) with acute bronchitis. Acta Paediatrica
99 (4), 537–543.
Linde, K., Streng, A., Ju¨rgens, S., Hoppe, A., Brinkhaus, B., Witt, C., Wagenpfeil, S.,
Pfaffenrath, V., Hammes, M., Weidenhammer, W., Willich, S., Melchart, D., 2005.
Acupuncture for patients with migraine: a randomized controlled trial. JAMA 293 (17),
2118–2125.
Miles, D. W., Chan, A., Dirix, L. Y., Corte´s, J., Pivot, X., Tomczak, P., Delozier, T., Sohn,
J. H., Provencher, L., Puglisi, F., Harbeck, N., Steger, G. G., Schneeweiss, A., Wardley,
A. M., Chlistalla, A., Romieu, G., Jul 10 2010. Phase III study of bevacizumab plus
27
docetaxel compared with placebo plus docetaxel for the first-line treatment of human
epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of Clinical
Oncology 28 (20), 3239–3247, doi: 10.1200/JCO.2008.21.6457.
Parmar, M. K. B., Torri, V., Stewart, L., 1998. Extracting summary statistics to perform
meta-analyses of the published literature for survival endpoints. Statistics in Medicine
17, 2815–2834.
Puhan, M. A., Schu¨nemann, H. J., Murad, M. H., Li, T., Brignardello-Petersen, R., Singh,
J. A., Kessels, A. G., Guyatt, G. H., GRADE Working Group, Sep 24 2014. A GRADE
working group approach for rating the quality of treatment effect estimates from network
meta-analysis. British Medical Journal 349, g5630, doi: 10.1136/bmj.g5630.
R Core Team, 2014. R: A Language and Environment for Statistical Computing. R Foun-
dation for Statistical Computing, Vienna, Austria.
URL http://www.R-project.org
Ru¨cker, G., 2012. Network meta-analysis, electrical networks and graph theory. Research
Synthesis Methods 3 (4), 312–324.
Ru¨cker, G., 2016. Network meta-analysis. Wiley StatsRef: Statistics Reference Online, pp.
1–8, stat07909.
URL http://onlinelibrary.wiley.com/doi/10.1002/9781118445112.stat07909/
abstract
Ru¨cker, G., Schwarzer, G., 2014. Reduce dimension or reduce weights? Comparing two
approaches to multi-arm studies in network meta-analysis. Statistics in Medicine 33,
4353–4369, dOI: 10.1002/sim.6236.
Ru¨cker, G., Schwarzer, G., Krahn, U., Ko¨nig, J., 2017. netmeta: Network meta-analysis
using frequentist methods. R package version 0.9-3.
URL http://cran.at.r-project.org/web/packages/netmeta/
Salanti, G., June 11 2012. Indirect and mixed-treatment comparison, network, or multiple-
treatments meta-analysis: many names, many benefits, many concerns for the next
28
generation evidence synthesis tool. Research Synthesis Methods 3 (2), 80–97.
URL doi:10.1002/jrsm.1037
The Cochrane Collaboration, 2014. Review Manager (RevMan) [Computer program]. Ver-
sion 5.3. Copenhagen: The Nordic Cochrane Centre.
Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., Sydes, M. R., Jun 7 2007. Practical
methods for incorporating summary time-to-event data into meta-analysis. Trials 8, 16.
Timmer, A., Gu¨nther, J., Motschall, E., Ru¨cker, G., Antes, G., Kern, W. V., 2013. Pelargo-
nium sidoides extract for treating acute respiratory tract infections. Cochrane Database
of Systematic Reviews (10).
Walsh, T., Worthington, H. V., Glenny, A.-M., Appelbe, P., Marinho, V. C., Shi, X.,
Jan 20 2010. Fluoride toothpastes of different concentrations for preventing dental
caries in children and adolescents. Cochrane Database of Systematic Reviews Doi:
10.1002/14651858.CD007868.pub2.
Xiao, W. J., Gutman, I., 2004. Relations between resistance and Laplacian matrices and
their applications. Match-Communications in Mathematical and in Computer Chem-
istry (51), 119–127.
Zier, L., Sievert, H., Mahadevan, V., Nov. 2016. To close or not to close: contemporary
indications for patent foramen ovale closure. Expert Rev Cardiovasc Ther. 14 (11),
1235–1244, doi: 10.1080/14779072.2016.1224178.
29
Comparison
Fixed effect model
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30 mg vs placebo
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0.0626
0.0783
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0.96
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[0.88; 1.13]
[0.78; 1.06]
[0.84; 1.10]
Weight
100.0%
40.5%
25.9%
33.6%
Figure 1: ‘Approximate adjustment’ for the pelargonium sidoides data.
Control 1
Active 1
Active 2
Control 3
Control 2
Figure 2: A multi-arm study with 2 active arms and 3 control arms.
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Comparison
Fixed effect model
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32.5%
Figure 3: ‘Exact adjustment’ for the pelargonium sidoides data.
Comparison to placebo
10 mg
20 mg
30 mg
placebo
0.9 1 1.1
Fixed Effect Model RR
1.00
0.91
0.96
1.00
95%−CI
[0.92; 1.09]
[0.82; 1.01]
[0.88; 1.06]
Figure 4: Network meta-analysis for the pelargonium sidoides data.
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Group
Fixed effect model
acupuncture
sham acupuncture
Total
226
145
 81
Mean
2.2
2.2
SD
2.7
2.7
Experimental
Total
76
38
38
Mean
0.8
0.8
SD
 2
 2
Control
−2 −1 0 1 2
Mean difference
Reduction in days with moderate or severe headache
MD
1.40
1.40
1.40
95%−CI
[0.82; 1.98]
[0.63; 2.17]
[0.53; 2.27]
Weight
100.0%
55.7%
44.3%
Figure 5: ‘Splitting the waiting list group’ for the acupuncture data.
Comparison
Fixed effect model
acupuncture vs waiting list
sham acupuncture vs waiting list
SE
0.3929
0.4625
−2 −1 0 1 2
Mean difference
Reduction in days with moderate or severe headache
MD
1.40
1.40
1.40
95%−CI
[0.81; 1.99]
[0.63; 2.17]
[0.49; 2.31]
Weight
100.0%
58.1%
41.9%
Figure 6: ‘Approximate adjustment’ for the acupuncture data.
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Comparison
Fixed effect model
acupuncture vs waiting list
sham acupuncture vs waiting list
SE
0.3637
0.4867
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Mean difference
Reduction in days with moderate or severe headache
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1.40
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1.40
95%−CI
[0.83; 1.97]
[0.69; 2.11]
[0.45; 2.35]
Weight
100.0%
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Figure 7: ‘Exact adjustment’ for the acupuncture data.
Treatment
acupuncture
sham acupuncture
waiting list
−2 −1 0 1 2
Fixed Effect Model MD
1.40
1.40
0.00
95%−CI
[0.77; 2.03]
[0.66; 2.14]
Figure 8: Network meta-analysis of the acupuncture data.
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Comparison
Fixed effect model
docetaxel + bevacizumab 15 vs docetaxel + placebo
docetaxel + bevacizumab 7.5 vs docetaxel + placebo
SE
0.1168
0.1149
0.75 1 1.5
Hazard Ratio HR
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0.86
95%−CI
[0.69; 0.96]
[0.61; 0.97]
[0.69; 1.08]
Weight
100.0%
49.2%
50.8%
Figure 9: ‘Approximate adjustment’ for the breast cancer data.
Comparison
Fixed effect model
docetaxel + bevacizumab 15 vs docetaxel + placebo
docetaxel + bevacizumab 7.5 vs docetaxel + placebo
SE
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0.1142
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Hazard Ratio HR
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Weight
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Figure 10: ‘Exact adjustment’ for the breast cancer data.
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Treatment
docetaxel 100 + bevacizumab 15
docetaxel 100 + bevacizumab 7.5
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Fixed Effect Model HR
0.77
0.86
1.00
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[0.64; 0.93]
[0.72; 1.03]
Figure 11: Network meta-analysis of the breast cancer data.
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